Chapter 77 Chapter 77 Estrogen and Estrogen Analogs for Prevention and Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

Slides:



Advertisements
Similar presentations
Preventing Bone Loss in Early Postmenopausal Women A CME Slide Library From the Council on Hormone Education.
Advertisements

Women's Health Initiative
Chapter 68 Chapter 68 Fracture Risk Assessment: The Development and Application of FRAX ® Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 67 Chapter 67 Biochemical Markers of Bone Turnover in Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 31 Chapter 31 Clinical and Epidemiological Studies: Skeletal Changes across Menopause Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 29 Chapter 29 Physical Activity and Exercise in the Maintenance of the Adult Skeleton and the Prevention of Osteoporotic Fractures Copyright ©
Chapter 85 Chapter 85 Parathyroid Hormone Treatment for Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
1 Chapter 58 - Clinical Syndromes of Metabolic Alkalosis Copyright © 2013 Elsevier Inc. All rights reserved.
1 Copyright © 2010, Elsevier Inc. All rights Reserved Fig 6.1 Chapter 6.
Chapter 53 Chapter 53 Osteogenesis Imperfecta and Other Defects of Bone Development as Occasional Causes of Adult Osteoporosis Copyright © 2013 Elsevier.
1 Chapter 69 - Clinical Disturbances of Phosphate Homeostasis Copyright © 2013 Elsevier Inc. All rights reserved.
1 Chapter 43 - The Urine Concentrating Mechanism and Urea Transporters Copyright © 2013 Elsevier Inc. All rights reserved.
1 Copyright © 2013 Elsevier Inc. All rights reserved. Chapter 14.
1 Chapter 35 - Mineralocorticoid Action in the Aldosterone Sensitive Distal Nephron Copyright © 2013 Elsevier Inc. All rights reserved.
1 Chapter 77 - Ischemic Renal Disease Copyright © 2013 Elsevier Inc. All rights reserved.
1 Chapter 40 - Physiology and Pathophysiology of Diuretic Action Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 83 Chapter 83 Denosumab for the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 84 Chapter 84 Strontium Ranelate in the Prevention of Osteoporotic Fractures Copyright © 2013 Elsevier Inc. All rights reserved.
WHAT IS Osteoporosis ? Osteoporosis is a common disease in the whole world, the danger in that disease is that you can't figure out if you have it early,
Chapter 72 Chapter 72 Calcium in the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 54 Chapter 54 HIV and Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
Food and Drug Administration Regulatory Implications of The WHI Study Eric Colman, MD Center for Drug Evaluation and Research Division of Metabolic and.
Endometrial and other cancers David W. Sturdee. Unopposed estrogen and endometrial cancer Smith Ziel –7.6 Mack19768 Antunes19796–15 Jick
WHI Trial of Estrogen plus Progestin: Reviewer’s Comments Endocrinologic and Metabolic Drugs Advisory Committee Meeting Rockville, Maryland - 7 October.
Chapter 41: Role of Sex Steroids in the Pathogenesis of Osteoporosis Matthew T. Drake and Sundeep Khosla.
Date of download: 5/31/2016 From: Alendronate and Estrogen–Progestin in the Long-Term Prevention of Bone Loss: Four-Year Results from the Early Postmenopausal.
Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Estrogen Plus Progestin and Breast Cancer Incidence.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Menopausal Hormone Therapy and Health Outcomes During.
Copyright © 2005 American Medical Association. All rights reserved.
Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis  Peyman Hadji  Critical Reviews in Oncology.
Copyright © 2015 by the American Osteopathic Association.
Modeling Constraints with Parametrics
Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate  Wulf H Utian, M.D.,
Effect of vitamin E supplementation with and without hormone therapy on circulatory inflammatory markers in postmenopausal women  Bruce R. Carr, M.D.,
Copyright © 2016 Elsevier Inc. All rights reserved.
Bisphosphonate exposure and Atypical Femoral Fractures
Copyright © 2012, Elsevier Inc. All rights Reserved.
Chapter 11.
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2012, Elsevier Inc. All rights Reserved.
Volume 13, Issue 5, Pages (May 2012)
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2012, Elsevier Inc. All rights Reserved.
Chapter 10.
Copyright © 2012, Elsevier Inc. All rights Reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Portable Biotechnology
© 2012 Elsevier, Inc. All rights reserved.
Modeling Functionality with Use Cases
Copyright © 2012, Elsevier Inc. All rights Reserved.
Chapter 91 Epidemiology of Headache in Women:
Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 12.
Chapter 6.
Copyright © 2012, Elsevier Inc. All rights Reserved.
Chapter 44 Osteoporosis: The Early Years
© 2012 Elsevier, Inc. All rights reserved.
Chapter 103 Long-Term Care: The Global Impact
Chapter 01.
Copyright © 2013 Elsevier Inc. All rights reserved.
Estrogen and progestogen therapy in postmenopausal women
Copyright © 2012, Elsevier Inc. All rights Reserved.
Chapter 15 Contraception
Chapter 78 Vaccination and Screening in Cervical Cancer
Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 15.
Chapter 77 Cervical Cancer: Burden of Disease
Chapter 20 Assisted Reproductive Technologies
Chapter 3.
Presentation transcript:

Chapter 77 Chapter 77 Estrogen and Estrogen Analogs for Prevention and Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

FIGURE 77.1 Spine bone mineral density changes for modified intention-to-treat for conjugated equine estrogens (CEEs) and CEEs–medroxyprogesterone acetate (MPA). Adjusted mean percentage changes (SE) in spine BMD are shown for the modified intention-to-treat (A and C) and efficacy-evaluable (B and D) populations for both the CEEs alone (A, B) and CEEs-MPA groups (C, D). Source: Lindsay, R. et al. JAMA 2002;287:2668– 2676, Used with permission [8]. 2

Copyright © 2013 Elsevier Inc. All rights reserved. FIGURE 77.2 Changes in bone markers for the Modified Intention-to-Treat (MITT) population for conjugated equine estrogens (CEEs) only and CEEs–medroxyprogesterone acetate (MPA) groups. Adjusted median percentage changes in urinary N-telopeptides of type I collagen (A) and serum osteocalcin (B) for the MITT population over time for the CEEs alone and placebo groups on the left and the CEEs-MPA and placebo groups on the right. Source: Lindsay, R. et al. JAMA 2002;287:2668–2676, used with permission [8]. 3

Copyright © 2013 Elsevier Inc. All rights reserved. FIGURE 77.3 Bioavailable E2 levels in three groups of Rochester, MN, men and in post- and premenopausal Rochester women. Source: Khosla S et al. JCEM 2001;86:3555–3561, used with permission [48]. 4

Copyright © 2013 Elsevier Inc. All rights reserved. FIGURE 77.4 The ratio of total body bone mineral content to lean body mass plotted against age. Source: reprinted from Jarvinen TL, Kannus P, Sievanen H Estrogen and bonea reproductive and locomotive perspective. J Bone Miner Res 18(11):1921–31. Copyright © John Wiley & Sons. Reprinted with permission [56]. 5

Copyright © 2013 Elsevier Inc. All rights reserved. FIGURE 77.5 Risk of breast cancer over 4 years in the placebo and raloxifene groups according to baseline serum estradiol level. Source: Cummings, S. R. et al. JAMA 2002;287:216–220. Used with permission [65]. 6

Copyright © 2013 Elsevier Inc. All rights reserved. FIGURE 77.6 Cases per 10,000 women per year in the estrogen therapy treatment and placebo groups in the Womens Health Initiative by age group. Adapted from Gass M, Bassuk S, Manson J. Am J Lifestyle Med 2009;3:29–43. 7

Copyright © 2013 Elsevier Inc. All rights reserved. FIGURE 77.7 Cases per 10,000 per year in the estrogen progestin therapy and placebo groups of the Womens Health Initiative study by age. Adapted from Gass M, Bassuk S, Manson J. Am J Lifestyle Med 2009;3:29–43. 8

Copyright © 2013 Elsevier Inc. All rights reserved. FIGURE 77.8 Molecular structures of estrodiol and estrogen analogs. 9